TP53 and prostate carcinoma: Additionally, in the study conducted by Mohammed Saleem and Selim [124] using different models of prostate cancer (LNCaP, p53+/+; 22RV1, p53−/+, and PC3, p53−/−), EA was reported as effective in reducing MDM2 at the gene and protein levels in all investigated cancer cell lines.